TCRX
TScan Therapeutics, Inc.
Key Financials
Net Income
$-129766000
↓ 1.8%
Operating Income
$-135813000
↓ 0.7%
Revenue
$10.3M
↑ 266.7%
EPS (Diluted)
$-1.00
↑ 12.3%
Shareholders' Equity
$123.1M
↓ 48.9%
Total Assets
$228.8M
↓ 38.4%
Total Liabilities
$105.7M
↓ 18.8%
Cash & Equivalents
$152.4M
↓ 14.7%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| ARS | 4/17/2026 | View on SEC |
| DEF 14A | 4/17/2026 | View on SEC |
| PRE 14A | 4/7/2026 | View on SEC |
| 8-K | 4/2/2026 | View on SEC |
| S-8 | 3/4/2026 | View on SEC |
| 10-K | 3/4/2026 | View on SEC |
| 8-K | 3/4/2026 | View on SEC |
| 4 | 1/22/2026 | View on SEC |
| 4 | 1/22/2026 | View on SEC |
| 4 | 1/22/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | TCRX |
| Company Name | TScan Therapeutics, Inc. |
| CIK | 1783328 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 857-399-9500 |